Monoclonal antibodies are clones of a single antibody that are developed as drug therapies. Monoclonal antibodies have been used as experimental treatments of MS from past 30years as their advantage is high specificity for their target. Past experience with monoclonal antibodies has taught researchers to interpret results seen in animal models with caution. Anti-TNFα antibodies are successful in the treatment by using animal model of MS (experimental autoimmune encephalomyelitis, EAE) suggested a beneficial effect on the disease. In MS, this means that, if antibodies can be identified that bind to cells that are involved in attacking nerve cells and causing disease activity, treatments could be developed that would only affect those cells.